Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

141. Global burden of cervical cancer among women living with HIV - a systematic review, meta-analysis and modelling study

Global burden of cervical cancer among women living with HIV - a systematic review, meta-analysis and modelling study Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

142. Assessment of the relative effectiveness and safety of vaginal microbicides for preventing sexually transmitted hiv infection: a network meta-analysis

Assessment of the relative effectiveness and safety of vaginal microbicides for preventing sexually transmitted hiv infection: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

143. Pediatric to adult transitional frameworks for HIV-infected adolescents in Sub-Saharan Africa: an integrative review

Pediatric to adult transitional frameworks for HIV-infected adolescents in Sub-Saharan Africa: an integrative review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

144. Prevalence of metabolic syndrome in people living with HIV on antiretroviral therapy: a systematic review and meta-analysis

Prevalence of metabolic syndrome in people living with HIV on antiretroviral therapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

145. Nutritional interventions aiming to improve body composition in persons living with HIV: a systematic review of clinical studies

Nutritional interventions aiming to improve body composition in persons living with HIV: a systematic review of clinical studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

146. A comparative analysis of physical fitness of children and adolescents with HIV infection: a systematic review protocol

A comparative analysis of physical fitness of children and adolescents with HIV infection: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

147. Medical and surgical abortion for women living with HIV. (PubMed)

Medical and surgical abortion for women living with HIV. The World Health Organization (WHO) guidelines for safe abortion recommend medical abortion with mifepristone and misoprostol or surgical abortion with vacuum aspiration or dilation and evacuation as safe and effective options for women. However, no specific clinical considerations are stipulated within these guidelines for women living with HIV. Concerns have been raised that women living with HIV may be at greater risk of adverse (...) abortion outcomes compared to HIV-uninfected women due to immunosuppression, high rates of co-infection with other sexually transmitted infections, and possible contraindications between medications used for medical abortion and antiretroviral therapy regimens.Our primary objective was to assess the effectiveness and safety of medical versus surgical abortion among women living with HIV. Our secondary objectives were to: (1) compare outcomes of medical and surgical abortion between women living

2018 Cochrane

148. HIV infection in pregnancy

HIV infection in pregnancy HIV infection in pregnancy - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  HIV infection in pregnancy Last reviewed: February 2019 Last updated: December 2018 Important updates 18 Dec 2018 Dolutegravir should not be used during the first trimester of pregnancy The US Department of Health and Human Services has updated its guidance on the management of pregnant women living with HIV (...) Food and Drug Administration and the European Medicines Agency both issued alerts about this risk in May 2018. These recommendations will be revised, if necessary, as additional data becomes available in 2019. Summary All pregnant women should be tested for HIV as early as possible in pregnancy. Repeat testing is recommended in the third trimester for pregnant women with initial negative tests who are known to be at risk of acquiring HIV. HIV-exposed infants should be tested for HIV infection

2018 BMJ Best Practice

149. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium

British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018) Suneeta Soni, Paddy Horner, Michael Rayment, Nicolas Pinto-Sander, Nadia Naous, Andy Parkhouse, Darren Bancroft, Carl Patterson, Helen Fifer 2 Introduction This is the first British Association of Sexual Health and HIV (BASHH) guideline (...) recommendations were presented at the joint British HIV Association and BASHH annual conference 2018. The draft guideline was appraised by the CEG using the AGREE instrument, posted on the BASHH website for a consultation period of 2 months, and piloted in a sample of clinics. In response to the consultation, suitable amendments were made to the guideline and the final draft was submitted to the CEG. The patient information leaflet (PIL) was reviewed by the CEG, BASHH patient and public panel, and also

2018 British Association for Sexual Health and HIV

150. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) adults infected with human immunodeficiency virus-1 (HIV-1)

Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) adults infected with human immunodeficiency virus-1 (HIV-1) AWMSG SECRETARIAT ASSESSMENT REPORT Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ) 50 mg/200 mg/25 mg film-coated tablets Reference number: 3414 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) University Hospital (...) from the date of the Final Appraisal Recommendation. AWMSG Secretariat Assessment Report Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ? ) 50 mg/200 mg/25 mg film-coated tablets 1.0 KEY FACTS Assessment details Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy ® ? ) for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. ?This medicinal

2018 All Wales Medicines Strategy Group

151. HIV self-testing at the workplace

HIV self-testing at the workplace POLICY BRIEF HIV TESTING SERVICES HIV SELF-TESTING AT THE WORKPLACE NOVEMBER 2018 Despite considerable scale-up of HIV testing services, many people are left behind, particularly men, adolescents, young women, and members of key populations 1 . Without further scale-up of strategies that make HIV testing services more convenient and appealing to those in need, it will be difficult to reach the United Nations 90–90–90 targets for 2020 – the first of which (...) is diagnosing 90% of all people with HIV. HIV self-testing (HIVST) is a testing option recommended by WHO that can be used to reach as-yet undiagnosed populations. According to the latest reports 2 , 59 countries have adopted HIVST policies as of June 2018, and many others are developing them. Photos clockwise: Re-Action, South Africa; Re-Action, South Africa; ILO; Sibanye-Stillwater, South Africa. 1 The WHO defines key populations as groups who, due to specific higher-risk behaviours and barriers

2018 World Health Organisation HIV Guidelines

152. Postpartum women living with HIV: Challenges related to retention in care, treatment adherence, and mental health

Postpartum women living with HIV: Challenges related to retention in care, treatment adherence, and mental health Postpartum women living with HIV: Challenges related to retention in care, treatment adherence, and mental health | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Postpartum women living with HIV: Challenges related to retention in care, treatment adherence, and mental health Postpartum women living with HIV: Challenges related to retention in care, treatment (...) adherence, and mental health , , , , Questions What are the challenges related to retention in HIV care during the postpartum period? What are the challenges related to HIV treatment adherence during the postpartum period? What are the challenges related to postpartum depression among women living with HIV? What effective interventions or promising practices can be used to support women with the above issues (particularly interventions by social workers, community workers and peers)? Key take-home

2018 Ontario HIV Treatment Network

153. HIV infection

HIV infection HIV infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  HIV infection Last reviewed: February 2019 Last updated: March 2019 Important updates 09 Nov 2018 US guidelines now recommend doravirine for the treatment of HIV Updated guidelines published by the US Department of Health and Human Services now recommend doravirine-based antiretroviral regimens as an initial option for the treatment of HIV (...) -nucleoside reverse transcriptase inhibitor (NNRTI), was approved by the US Food and Drug Administration in August 2018 in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment history. The drug is available as a single-ingredient formulation or in a co-formulation with lamivudine and tenofovir disoproxil. It has also been recommended for approval in Europe, with a final decision pending. Approval was based on two clinical trials

2018 BMJ Best Practice

154. External quality assessment for HIV rapid tests: challenges and opportunities in Haiti (PubMed)

External quality assessment for HIV rapid tests: challenges and opportunities in Haiti HIV rapid diagnostic tests (RDTs) are instrumental in scaling-up HIV testing services (HTS) in low-income and middle-income countries (LMICs). HIV misdiagnosis is a growing concern in the era of expanded and decentralised access to HTS. External quality assurance (EQA) programme including proficiency testing (PT) for HIV RDTs is a priority to guarantee the accuracy and reliability of the patients' result (...) . Here we are sharing Haiti's 11 years' experience in implementing HIV RDTs EQA programme to help address some of the challenges faced by other LMICs. HTS is expanding beyond laboratory walls and HIV RDTs are increasingly performed by non-laboratory personnel and closer to the community. EQA programmes for HIV RDTs in Haiti have faced significant challenges. In expanded HTS settings, non-laboratory personnel (nurses, aid-nurses) involved in HIV RDT are usually undertrained and participate poorly

Full Text available with Trip Pro

2018 BMJ global health

155. The pull of soccer and the push of Xhosa boys in an HIV and drug abuse intervention in the Western Cape, South Africa (PubMed)

The pull of soccer and the push of Xhosa boys in an HIV and drug abuse intervention in the Western Cape, South Africa There is growing interest in engaging men and boys in health and development programmes targeting the intersection of HIV risk, substance abuse, and violence. Understanding the conceptualisations of masculinities or masculine identities that shape both behaviours and opportunities for intervention is central to advancing the global agenda to engage men in health and development (...) interventions. This paper examines an intervention using soccer and job training to engage and deliver activities for HIV prevention, substance abuse, and gender-based violence in a South African township. A literature review provides theoretical, historical and social context for the intersection of gender, masculinity, soccer, violence, and sexual relationships. Qualitative data from in-depth interviews and focus groups is analysed using theoretical and contextual frames to elucidate the negotiation

Full Text available with Trip Pro

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

156. Antiretroviral resistance testing in HIV-positive people. (PubMed)

Antiretroviral resistance testing in HIV-positive people. Resistance to antiretroviral therapy (ART) among people living with human immunodeficiency virus (HIV) compromises treatment effectiveness, often leading to virological failure and mortality. Antiretroviral drug resistance tests may be used at the time of initiation of therapy, or when treatment failure occurs, to inform the choice of ART regimen. Resistance tests (genotypic or phenotypic) are widely used in high-income countries (...) , but not in resource-limited settings. This systematic review summarizes the relative merits of resistance testing in treatment-naive and treatment-exposed people living with HIV.To evaluate the effectiveness of antiretroviral resistance testing (genotypic or phenotypic) in reducing mortality and morbidity in HIV-positive people.We attempted to identify all relevant studies, regardless of language or publication status, through searches of electronic databases and conference proceedings up to 26 January 2018. We

2018 Cochrane

157. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior (PubMed)

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared with a three-drug regimen (...) for the treatment of HIV-1 infection in ART-naive adults.We conducted two identically designed, multicentre, double-blind, randomised, non-inferiority, phase 3 trials: GEMINI-1 and GEMINI-2. Both studies were done at 192 centres in 21 countries. We included participants (≥18 years) with HIV-1 infection and a screening HIV-1 RNA of 500 000 copies per mL or less, and who were naive to ART. We randomly assigned participants (1:1) to receive a once-daily two-drug regimen of dolutegravir (50 mg) plus lamivudine (300

2018 Lancet

158. HIV-related opportunistic infections

HIV-related opportunistic infections HIV-related opportunistic infections - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  HIV-related opportunistic infections Last reviewed: February 2019 Last updated: November 2018 Summary The risk of HIV-related opportunistic infections (OIs) in HIV-infected people increases as the CD4+ count declines. Risk also increases in patients who are not receiving, or are not responding (...) to, antiretroviral treatment (ART). For most HIV-infected patients with an acute OI, ART should be considered within the first 2 weeks of initiation of treatment for the acute OI. However, in tuberculosis (TB) it might be appropriate to wait for a therapeutic response before ART is started. The use of ART among patients treated for OIs is complicated by drug interactions, drug toxicity profiles, and immune reconstitution inflammatory syndrome (IRIS). IRIS has been observed most commonly with mycobacterial

2018 BMJ Best Practice

159. Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV

Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV , , , , , , , Questions What is the efficacy of oral tenofovir disoproxil fumarate with or without emtricitabine as pre-exposure prophylaxis (PrEP) for HIV in the context (...) of clinical trials? Has this efficacy been realized in real-world implementation? What are the key factors implicated in its efficacy and what is the frequency of breakthrough infections? Key take-home messages Oral PrEP (tenofovir disoproxil fumarate with emtricitabine) is highly protective against HIV acquisition across various populations and across different dosing schedules (1, 2). Open label and demonstration projects in both high- and low-income country settings have shown that oral tenofovir

2018 Ontario HIV Treatment Network

160. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V

Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Darunavir/Cobicistat/Emtricitabine/Tenofoviralafenamid (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 22 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A17-48 Darunavir/cobicistat/ emtricitabine/tenofovir alafenamide (HIV infection) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-48 Version 1.0 Darunavir/cobicistat/ emtricitabine/tenofovir alafenamide (HIV infection) 22 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Darunavir

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)